
Injectable products contaminated with visible particulates, such as glass or rubber, can cause severe complications including inflammation, tissue damage or embolic events. The pharmaceutical industry must prioritize improving inspection practices and aligning with FDA guidance to prevent such contamination and ensure patient safety.